Tumor suppressor SMAR1 downregulates Cytokeratin 8 expression by displacing p53 from its cognate site

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 4, 2009, Pages 862-871

  Pavithra, Lakshminarasimhan ^a   Singh, Sandeep ^a   Sreenath, Kadreppa ^a   Chattopadhyay, Samit ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Breast cancer; Cytokeratin 8; HDAC1; p53; Peroxide stress; SMAR1

Indexed keywords

CYTOKERATIN 8; PROTEIN P53; SMAR1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; CELL INVASION; CELL MIGRATION; CELL STRAIN MCF 7; CELL SURFACE; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSACTIVATION; WESTERN BLOTTING;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMATIN; DNA DAMAGE; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KERATIN-8; LUNG NEOPLASMS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59849093564     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.08.038     Document Type: Article

References (31)

1. Bichat F., Mouawad R., Solis-Recendez G., Khayat D., and Bastian G. Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 17 (1997) 3393-3401
2. Brotherick I., Robson C.N., Browell D.A., Shenfine J., White M.D., Cunliffe W.J., Shenton B.K., Egan M., Webb L.A., Lunt L.G., Young J.R., and Higgs M.J. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 32 (1998) 301-308
3. Chattopadhyay S., Kaul R., Charest A., Housman D., and Chen J. SMAR1, a novel, alternatively spliced gene product, binds the scaffold/matrix-associated region at the T cell receptor beta locus. Genomics 68 (2000) 93-96
4. Erber A., Riemer D., Bovenschulte M., and Weber K. Molecular phylogeny of metazoan intermediate filament proteins. J Mol Evol 47 (1998) 751-762
5. Ferrero M., Spyratos F., Le D., Desplaces A., and Rouesse J. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. Cytometry 11 (1990) 716-724
6. Gunther M., Frebourg T., Laithier M., Fossar N., Bouziane-Ouartini M., Lavialle C., and Brison O. An Sp1-binding site and the minimal promoter contribute to overexpression of the cytokeratin 18 gene in tumorigenic clones relative to that in nontumorigenic clones of a human carcinoma cell line. Mol Cell Biol 15 (1995) 2490-2499
7. Hembrough T.A., Kralovich K.R., Li L., and Gonias S.L. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. Biochem J 317 Pt 3 (1996) 763-769
8. Hembrough T.A., Li L., and Gonias S.L. Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. J Biol Chem 271 (1996) 25684-25691
9. Holtzer H, Fellini S, Rubeinstein N, Chi J, Strahs K. Cells, myosin and 100 A filaments. Cold Spring Harbour Conf. Cell. Proliferation Book A 1976; 823-839.
10. Iwaya K., Ogawa H., Mukai Y., Iwamatsu A., and Mukai K. Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. Cancer Sci 94 (2003) 864-870
11. Jalota-Badhwar A., Kaul-Ghanekar R., Mogare D., Boppana R., Paknikar K.M., and Chattopadhyay S. SMAR1-derived P44 peptide retains its tumor suppressor function through modulation of p53. J Biol Chem 282 (2007) 9902-9913
12. Kaul R., Mukherjee S., Ahmed F., Bhat M.K., Chhipa R., Galande S., and Chattopadhyay S. Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice. Int J Cancer 103 (2003) 606-615
13. Kim S., and Coulombe P.A. Intermediate filament scaffolds fulfill mechanical, organizational, and signaling functions in the cytoplasm. Genes Dev 21 (2007) 1581-1597
14. Korsching E., Packeisen J., Bocker W., and Burger H. Bootstrapping approach reveals inherent regulatory pattern in 550 invasive breast cancer cases: CK5/6/CK14 and CK8/18/CK19 builds an antagonistic set. Verh Dtsc Ge Pathol 89 (2005) 207-210
15. Ku N.O., and Omary M.B. Keratins turn over by ubiquitination in a phosphorylation-modulated fashion. J Cell Biol 149 (2000) 547-552
16. Ledinko N., and Costantino R.L. Modulation of p53 gene expression and cytokeratin 18 in retinoid-mediated invasion suppressed lung carcinoma cells. Anticancer Res 10 (1990) 1335-1339
17. Mukhopadhyay T., and Roth J.A. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines. Anticancer Res 16 (1996) 105-112
18. Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., and George D.L. Transcriptional repression by wild-type p53 histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13 (1999) 2490-2501
19. Navarro J.M., Casatorres J., and Jorcano J.L. Elements controlling the expression and induction of the skin hyperproliferation-associated keratin K6. J Biol Chem 270 (1995) 21362-21367
20. Oshima R.G. Apoptosis and keratin intermediate filaments. Cell Death Differ 9 (2002) 486-492
21. Pavithra L., Rampalli S., Sinha S., Sreenath K., Pestell R.G., and Chattopadhyay S. Stabilization of SMAR1 mRNA by PGA2 involves a stem loop structure in the 5′ UTR. Nucleic Acids Res 35 (2007) 6004-6016
22. Prochasson P., Delouis C., and Brison O. Transcriptional deregulation of the keratin 18 gene in human colon carcinoma cells results from an altered acetylation mechanism. Nucleic Acids Res 30 (2002) 3312-3322
23. Rampalli S., Pavithra L., Bhatt A., Kundu T.K., and Chattopadhyay S. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol Cell Biol 25 (2005) 8415-8429
24. Raul U., Sawant S., Dange P., Kalraiya R., Ingle A., and Vaidya M. Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype. Int J Cancer 111 (2004) 662-668
25. Singh K., Mogare D., Giridharagopalan R.O., Gogiraju R., Pande G., and Chattopadhyay S. p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion. PLoS ONE 2 (2007) e660
26. Takei H., Iino Y., Horiguchi J., Kanoh T., Takao Y., Oyama T., and Morishita Y. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma. Anticancer Res 15 (1995) 1101-1105
27. Tripathi M.K., Misra S., and Chaudhuri G. Negative regulation of the expressions of cytokeratins 8 and 19 by SLUG repressor protein in human breast cells. Biochem Biophys Res Commun 329 (2005) 508-515
28. Tsubura A., Okada H., Senzaki H., Hatano T., and Morii S. Keratin expression in the normal breast and in breast carcinoma. Histopathology 18 (1991) 517-522
29. Willipinski-Stapelfeldt B., Riethdorf S., Assmann V., Woelfle U., Rau T., Sauter G., Heukeshoven J., and Pantel K. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11 (2005) 8006-8014
30. Wynford-Thomas D., and Blaydes J. The influence of cell context on the selection pressure for p53 mutation in human cancer. Carcinogenesis 19 (1998) 29-36
31. Xu X.C., Lee J.S., Lippman S.M., Ro J.Y., Hong W.K., and Lotan R. Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis. Cancer Epidemiol Biomarkers Prevent 4 8 (1995) 871-876